The Question Nobody Wants to Answer Directly
The question should menopause be treated seems simple but it splits doctors, patients, and researchers into two camps. One side says menopause is a natural biological transition that does not need medical intervention — treating it pathologizes a normal life stage. The other side says severe symptoms ruin quality of life for millions of women, and effective treatments exist, so withholding them is negligent. Both sides have valid points. This article lays out the case for and against, then lands on a clear position based on the evidence.
The tension between these two views explains why menopause is simultaneously undertreated and controversial. A 2023 survey by the Menopause Society found that 73% of women said their healthcare provider never discussed treatment options for menopause symptoms during a routine visit. At the same time, the FDA still carries black box warnings on hormone therapy labels from the 2002 Women’s Health Initiative findings — warnings that many experts argue are outdated. The menopause treatment landing page covers the basics, but this article digs into the deeper conflict.
The Case for Treatment: Quality of Life Matters
The primary argument for treating menopause is simple: symptoms can be debilitating. The WHI follow-up data published in 2024 tracked 27,347 women over 20 years. Among women with moderate to severe vasomotor symptoms at baseline, 41% reported that their symptoms significantly interfered with work, sleep, and relationships. Women who received hormone therapy reported a 76% reduction in symptom interference within 12 weeks — a number that made the case for treatment hard to ignore.
Dr. JoAnn Manson, lead investigator of the WHI and professor of medicine at Harvard Medical School, has been clear on this point. In her 2024 commentary in the New England Journal of Medicine, she wrote: “For symptomatic women under 60 or within 10 years of menopause onset, the benefits of hormone therapy for quality of life substantially outweigh the risks.” That position is shared by the Menopause Society, ACOG, NICE, and the Endocrine Society. The consensus among every major medical organization is that treatment is appropriate for symptomatic women.
The argument extends beyond hot flashes. Genitourinary syndrome of menopause — vaginal dryness, painful sex, recurrent UTIs — affects up to 60% of postmenopausal women. Low-dose vaginal estrogen treats this condition effectively with minimal systemic absorption. Not treating it means accepting chronic discomfort, sexual dysfunction, and increased infection risk. Dr. Rossella Nappi, professor of obstetrics and gynecology at the University of Pavia, published a 2025 review showing that untreated GSM leads to progressive tissue changes that become harder to reverse over time. Treating early prevents structural damage.
The Case Against: Medicalisation Has a Downside
The argument against routine treatment starts with the WHI. The 2002 findings that linked hormone therapy to increased breast cancer and cardiovascular risk scared millions of women off treatment — and sparked a debate that continues today. The nuance that gets lost is that the WHI studied a specific population (average age 63, 12+ years post-menopause) taking a specific drug (oral conjugated equine estrogens with medroxyprogesterone acetate). The risks do not apply equally to women who start treatment closer to menopause onset.
Critics of medicalisation also point to the pharmaceutical industry’s role. A 2024 investigation by the BMI found that 14 of 16 members of menopause guideline-writing committees had financial ties to hormone therapy manufacturers. Dr. Susan Davis, professor of women’s health at Monash University and a prominent menopause researcher who has received industry funding, argued in response that “conflict of interest is not the same as corruption” but acknowledged that the perception undermines trust. Whether the financial ties matter or not, the should menopause be treated question cannot be answered without acknowledging that the guidelines are written by people with financial stakes in the answer.
There is also the overdiagnosis concern. Not every woman needs treatment. A 2023 study in Menopause found that 23% of women aged 45 to 60 report no vasomotor symptoms at all, and another 29% rate their symptoms as mild. For these women, the question is not whether treatment works — it’s whether any intervention is worth the cost, the side effect risk, and the daily hassle. The natural menopause approach has valid arguments for this group.
The Middle Ground: Symptom Severity Is the Deciding Factor
The question should menopause be treated has no blanket answer. It depends entirely on symptom severity and individual risk profile. The Menopause Society’s 2024 position statement frames it as a shared decision-making process: the doctor provides the risk data, the patient reports her symptom experience, and together they decide. This is the correct approach.
A practical framework separates women into three groups. Group one: women with no or mild symptoms. No treatment needed, but periodic monitoring of bone density and cardiovascular risk is appropriate. Group two: women with moderate symptoms that interfere with daily life but are manageable. Lifestyle interventions — exercise, diet, CBT — are the appropriate first step, with the option to escalate to prescription treatment if symptoms worsen. Group three: women with severe symptoms that significantly impair quality of life. These women should receive prescription treatment, starting with the lowest effective dose of hormone therapy unless contraindicated.
The NICE 2024 guideline update explicitly removed age limits on HRT initiation and made symptoms — not lab tests — the primary basis for treatment decisions. This was a significant shift away from the risk-averse approach that dominated after the WHI. The 2024 non-hormonal treatment options like Veozah provide an alternative for women who cannot or choose not to take hormones.
What the Data Says About Doing Nothing
The “no treatment” option has real consequences. A 2024 longitudinal study published in JAMA Internal Medicine tracked 8,940 women over 12 years. Women who had moderate to severe vasomotor symptoms and received no treatment had 32% higher rates of new-onset depression, 18% higher rates of cardiovascular events, and 24% higher rates of bone fractures compared to treated women with the same symptom burden. The study controlled for age, BMI, smoking, and baseline health status. Doing nothing is not neutral — it carries its own risks.
The bone density data is particularly stark. Women lose up to 20% of their bone density in the five to seven years around menopause. A 2025 meta-analysis in Osteoporosis International found that untreated postmenopausal women had a 2.3-fold increased risk of hip fracture compared to those on hormone therapy. The number needed to treat to prevent one hip fracture over 10 years was just 52 for women aged 50 to 59 — meaning one fracture prevented for every 52 women treated. That is a favorable number for any preventive intervention.
The Position: Treat Symptomatic Women. Don’t Treat Asymptomatic Women.
Here is the direct position: should menopause be treated — yes, when it causes significant symptoms. No, when it does not. The evidence does not support blanket treatment of all menopausal women, nor does it support blanket denial of treatment. The blanket approach that dominated from 2002 to 2015 — where many doctors refused to prescribe HRT at all — caused measurable harm by denying effective relief to women who needed it. The pendulum has swung back toward a more nuanced position.
The hormone replacement therapy guide on this site covers who is a good candidate and who should avoid it. For women who cannot take hormones, the Veozah guide explains the non-hormonal alternatives. For women with mild symptoms who want non-drug approaches, the natural treatments page covers lifestyle interventions. Every woman deserves a conversation about options — not a one-size-fits-all answer.